The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats
Open accessAbstract
Activation of cannabinoid CB(2) receptors suppresses neuropathic pain induced by traumatic nerve injury. The present studies were conducted to evaluate the efficacy of cannabinoid CB(2) receptor activation in suppressing painful peripheral neuropathy evoked by chemotherapeutic treatment with the antitumor agent paclitaxel. Rats received paclitaxel (2 mg/kg i.p./day) on 4 alternate days to induce mechanical hypersensitivity (mechanical allodynia). Mechanical allodynia was defined as a lowering of the threshold for paw withdrawal to stimulation of the plantar hind paw surface with an electronic von Frey stimulator. Mechanical allodynia developed in paclitaxel-treated animals relative to groups receiving the Cremophor EL/ethanol/saline vehicle at the same times. Two structurally distinct cannabinoid CB(2) agonists, the aminoalkylindole (R,S)-AM1241 [(R,S)-(2-iodo-5-nitrophenyl)-[1-((1-methyl-piperidin-2-yl)methyl)-1H-indol-3-yl]-methanone] and the cannabilactone AM1714 (1,9-dihydroxy-3-(1',1'-dimethylheptyl)-6H-benzo[c]chromene-6-one), produced a dose-related suppression of established paclitaxel-evoked mechanical allodynia after systemic administration. Pretreatment with the CB(2) antagonist SR144528 [5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-N-(1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-pyrazole-3-carboxamide], but not the CB(1) antagonist SR141716 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide], blocked the antiallodynic effects of both (R,S)-AM1241 and AM1714. Moreover, (R)-AM1241, but not (S)-AM1241, suppressed paclitaxel-evoked mechanical allodynia relative to either vehicle treatment or preinjection thresholds, consistent with mediation by CB(2). Administration of either the CB(1) or CB(2) antagonist alone failed to alter paclitaxel-evoked mechanical allodynia. Moreover, (R,S)-AM1241 did not alter paw withdrawal thresholds in rats that received the Cremophor EL vehicle in lieu of paclitaxel, whereas AM1714 induced a modest antinociceptive effect. Our data suggest that cannabinoid CB(2) receptors may be important therapeutic targets for the treatment of chemotherapy-evoked neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that mixed CB 1 /CB 2 receptor agonists and CB 2 receptor-selective agonists are effective against paclitaxel-induced peripheral neuropathy (Deng et al, 2015a(Deng et al, , 2015b;;Pascual et al, 2005;Rahn et al, 2008).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Rahn et al, 2008
In the citing paper
“Interestingly, pre-treatment with the CB1 antagonist, SR141716, enhanced the effects of A-836339 when applied to the L5 DRG,88 indicating that blockade of CB1 receptors enhanced the antinociceptive effects of a CB2 agonist, as reported previously.89”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [89]
In the citing paper
“In this model, rats showed signs of mechanical allodynia up to 72 days post-paclitaxel.89”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [89]
In the citing paper
“(S)-AM1241, the enantiomer exhibiting lower affinity for the CB2 receptor, failed to produce an anti-allodynic effect.89”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [89]
In the citing paper
“The novel cannabilactone, AM1714, also reversed mechanical allodynia associated with paclitaxel treatment in a CB2-dependent manner.89”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [89]
In the citing paper
“Systemic administration of either the CB2 agonist (R,S)-AM1241 or its receptor-active enantiomer (R)-AM1241 produced CB2-mediated suppressions of paclitaxel-induced mechanical allodynia.”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
Self-citationTHE IMPACT OF NATIONAL CANCER ACT
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 744
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanus, L. O., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 581
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
Flatters, S. J. L., & Bennett, G. J. (2004) · Pain · doi:10.1016/j.pain.2004.01.029 · Cited by 576
Flatters, S. J. L., & Bennett, G. J. (2006) · Pain · doi:10.1016/j.pain.2006.01.037 · Cited by 536
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491
Self-citationA painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
Polomano, R. C., Mannes, A. J., Clark, U. S., & Bennett, G. J. (2001) · Pain · doi:10.1016/s0304-3959(01)00363-3 · Cited by 476
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–117 of 117
Cannabinoids to Fight Chemotherapy-Induced Adverse Effects
Bagüés, A., Benítez, D., & Abalo, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_350-2 · Cited by 1
Liverworts as a hidden secret for soothing inflammation and alleviating pain
Meireles-Medeiros, N., Oliveira, M. F., Perez, A. C., & Maciel‐Silva, A. S. (2025) · Botany · doi:10.1139/cjb-2024-0139 · Cited by 1
Astruc‐Diaz, F. (2012) · theses.fr (ABES) · doi:10.70675/de9cec28z5760z44baz93c9zce536330b49f · Cited by 1
Llames, S. G., Hidalgo, A., Menéndez, L., & Baamonde, A. (2010)
Cannabis in der Veterinärmedizin – Pharmakologie und Anwendungsbeispiele
Bruckner, S. (2021) · veterinär spiegel · doi:10.1055/a-1660-3524
Alternative Therapies for Chemotherapy-Induced Peripheral Neuropathy
Mao‐Ying, Q., Chen, Y., & Li, X. (2022) · Springer eBooks · doi:10.1007/978-3-030-96221-0_13
Resultados preclínicos de cannabinoides y dolor (algunos)
García, C. G., González, M. S., Martínez‐García, M. Á., Serrano, D. P., & Sánchez-Robles, E. (2022) · Revista de la Sociedad Española del Dolor · doi:10.20986/resed.2022.4033/2022
Cannabinoids to Fight Chemotherapy-Induced Adverse Effects
Bagüés, A., Benítez, D., & Abalo, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_350-1
Jesus, C. H. A., Reddy, G. R., Sizemore, E. F., Wirt, J. L., Sen, S., Yu, R. C., Takeuchi, T., Schwimmer, L. J., & Hohmann, A. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690750
Self-citationCannabinoids to Fight Chemotherapy-Induced Adverse Effects
Bagüés, A., Benítez, D., & Abalo, R. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_350
LEI‐101 produces broad‐spectrum analgesia in preclinical pain models
Yusuf, M., Benkli, A. B., & Yusuf, R. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70607
Vera, G., Cabezos, P. A., Martín, M. I., & Abalo, R. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.02.008 · Cited by 68
Metadata
- Authors
- Rahn, E. J., Zvonok, A. M., Thakur, G. A., Khanolkar, A. D., Makriyannis, A., & Hohmann, A. G.
- Affiliations
- University of Georgia (US)
- Northeastern University (US)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 327
- Issue
- 2
- Pages
- 584-591
- ISSN
- 0022-3565 (ISSN-L)
- PMC
- PMC2682949
- OpenAlex
- W2093570206
- Cited by
- 116
- References
- 41
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 7 · 2019: 10 · 2018: 10 · 2017: 8 · 2016: 4 · 2015: 2 · 2014: 6 · 2013: 6 · 2012: 11
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (DA3801, DA022478, DA-022702, DA 9158, R01DA003801, R21DA022478, R01DA021644, R37DA003801, R21DA022702, P01DA009158, DA021644)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- CB2 receptor, paclitaxel-induced neuropathic pain, chemotherapy-induced peripheral neuropathy, mechanical allodynia, CB2 receptor agonist, AM1241, SR144528, CB1 receptor, enantiomers, analgesia
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Cannabinoids, Chromones, Dimethyl Sulfoxide, Male, Morphine, Neuralgia, Stereoisomerism, Rats, Sprague-Dawley, Paclitaxel, Pain Threshold, Receptor, Cannabinoid, CB2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
